Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
- Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
- Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 176
- Registration Number
- NCT01011699
- Locations
- 🇫🇷
ALURAD, Limoges, Limousin, France
🇫🇷Centre Hospital-Universitaire d'Amiens, Amiens, Picardie, France
🇫🇷Centre Hospitalier, Cambrai, France
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 18
- Registration Number
- NCT00999037
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2011-11-18
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 20
- Registration Number
- NCT00967629
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Shire
- Target Recruit Count
- 31
- Registration Number
- NCT00875017
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 349
- Registration Number
- NCT00853242
Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Karolinska Institutet
- Registration Number
- NCT00837655
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪Sahlgrenska University Hospital, Gothenburg, Sweden
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 5
- Registration Number
- NCT00833768
- Locations
- 🇦🇹
Uniklinik für Innere Medizin IV, Nephrologie und Hypertensiologie, Zentrum für Innere Medizin, Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse, Vienna, Austria
🇬🇷Ippokrateio Hospital of Athens, Athens, Greece
Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2011-11-23
- Target Recruit Count
- 120
- Registration Number
- NCT00806481
- Locations
- 🇬🇧
University Hospital Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
- Conditions
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Denver Nephrologists, P.C.
- Target Recruit Count
- 148
- Registration Number
- NCT00785629
- Locations
- 🇺🇸
Denver Nephrologists, PC, Denver, Colorado, United States
Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Romanian Society of Nephrology
- Registration Number
- NCT00364000
- Locations
- 🇷🇴
"Dr Carol Davila" Teaching Hospital of Nephrology, Bucharest, Romania
🇷🇴"CI Parhon" Clinical Hospital, Iasi, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.